Anti-Human CD8 [Clone UCHT-4] — Purified in vivo PLATINUM™ Functional Grade
Anti-Human CD8 [Clone UCHT-4] — Purified in vivo PLATINUM™ Functional Grade
Product No.: C666
Clone UCHT-4 Target CD8 Formats AvailableView All Product Type Monoclonal Antibody Isotype Mouse IgG2a Applications FA , FC , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Thymocytes and Sézary T cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829809 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this UCHT-4 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood followed by PN:A104. Titration of the reagent is recommended for optimal performance for each application. WB The suggested concentration for this UCHT-4 antibody for use in western blotting is 1-10 μg/ml when used in conjunction with compatible secondary reagents, such as PN:R1190, under either reducing or non-reducing conditions. The positive control for Western blotting is PN:M1019 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone UCHT-4 recognizes human CD8. Background CD8 is made up of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8 is part of the Ig superfamily that expresses primarily as CD8a homodimers. CD8a is a 32-34 kD type I glycoprotein that can also form heterodimers with CD8b. CD8 is an antigen co-receptor on T cells that mediates efficient cell to cell interactions within the immune system. CD8 coupled with the T cell receptor on the T lymphocyte recognizes an antigen displayed by an antigen presenting cell (APC) in the context of class I MHC molecules. The CD8 co-receptor also plays a role in T cell signaling by interacting with Lck (lymphocyte-specific protein tyrosine kinase) which leads to the activation of transcription factors that affect the expression of certain genes. Antigen Distribution CD8 is expressed on blood lymphocytes, a subset of NK cells, and thymocytes. Persons with HIV exhibit increased levels of CD8+ lymphocytes. Ligand/Receptor MHC Class I molecules PubMed NCBI Gene Bank ID UniProt.org Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone UCHT-4 is a monoclonal antibody targeting human CD8, and in mice, it is commonly used in humanized mouse models for several in vivo immunological applications. The most frequent in vivo applications of UCHT-4 in mice include:
Key details:
In summary, UCHT-4 is primarily used for identification, depletion, and functional modulation of human CD8+ T cells in humanized mice for immunological research. Commonly used antibodies or proteins with UCHT-4 (a monoclonal anti-human CD8 antibody) in the literature include other antibodies that help distinguish different immune cell populations or define specific cell phenotypes in flow cytometry and immunological assays. Key antibodies and proteins frequently used with UCHT-4:
Summary table of common markers used with UCHT-4 (anti-CD8):
These antibody combinations are central to immunophenotyping in flow cytometry, immune monitoring, and basic immunology research. Clone UCHT-4 is a monoclonal antibody used to detect human CD8, a surface marker predominantly present on cytotoxic T cells and some regulatory T cell subsets. The key findings from scientific literature that cite clone UCHT-4 center on its value for identifying and isolating CD8+ T cells in immunology research and clinical diagnostic applications. Key findings from UCHT-4 citations include:
Citations of UCHT-4 commonly highlight its reliability and effectiveness in flow cytometry, immunohistochemistry, and related immunological assays. The literature does not report significant limitations or cross-reactivity issues, consolidating its reputation as a standard tool for CD8 detection. No contradictory findings regarding the function or specificity of clone UCHT-4 are apparent in the cited scientific literature. If you require more specific or recent findings from individual studies, please specify the application or context of interest. Dosing regimens for clone UCHT-4 anti-human CD8 antibody can vary depending on the specific mouse model and experimental context, but direct published data on precise dosing schedules for UCHT-4 across mouse models is limited. Most protocols rely on empirically determined dosing based on the mouse model, the desired level of CD8+ cell depletion, and the immunological environment. There are several key factors influencing regimen selection:
General empirical guidance for anti-CD8 depletion in mouse models (based on analogous clone protocols, as specific published UCHT-4 regimens are rare):
Variation Across Models:
No universal regimen applies, so researchers are advised to:
If the context specifically requires clone UCHT-4, and published protocols are unavailable, contacting suppliers (e.g., Leinco Technologies) for technical guidance or referencing closely related clones (e.g., OKT-4, RPA-T4) is recommended. In summary, clone UCHT-4 dosing regimens vary by mouse model, immune context, and experimental aim, with empirical titration needed for humanized settings. Published literature offers protocols for mouse anti-CD4 or anti-CD8 analogs, but direct UCHT-4 schedules are rarely specified. References & Citations1. Parnes, J. R. et al. (1989) Adv. Immunol. 44:265 2. Reinherz, E. L. et al. (1980) J. Immunol. 124:1301 3. Fischer, A. et al. (1983) Immunology 48:177 4. Merkenschlanger, M. et al. (1988) Eur. J. Immunol. 18:1653 5. Leukocyte Typing: 3rd Workshop: Code No. 567; 4th Workshop: Code No. N31 Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
S211 | |
R1364 | |
I-118 | |
M1188 | |
C247 | |
F1175 | |
S571 |
Formats Available
Prod No. | Description |
---|---|
C2068 | |
C117 | |
C120 | |
C118 | |
C119 | |
C2060 | |
C2061 | |
C2062 | |
C2064 | |
C2066 | |
C366 | |
C312 | |
C666 |
